Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune Suppression

Overview of attention for article published in Frontiers in immunology, June 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 21 news outlets
twitter: 9 X users

patent: 1 patent

Readers on

mendeley: 92 Mendeley

So far, Altmetric has seen 21 news stories from 21 outlets.

MNOV: Encouraging Phase 2 Glioblastoma Results Presented at SNO…

Yahoo! Finance USA, 27 Nov 2023

By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update New Data for MN-166 in GBM Presented at SNO…

MediciNova +14% on encouraging ibudilast data in glioblastoma

Seeking Alpha, 26 Jun 2020

MediciNova (NASDAQ: MNOV ) is up 14% premarket on positive preclinical findings published in Frontiers in Immunology regarding…

MediciNova Announces Positive Preclinical Results Regarding MN-166 (ibudilast) in Glioblastoma (GBM) Published in Frontiers in Immunology

USA Life Sciences Database, 26 Jun 2020

LA JOLLA, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global…

MediciNova Announces Positive Preclinical Results Regarding MN-166 (ibudilast) in Glioblastoma (GBM) Published in Frontiers in Immunology

NASDAQ, 26 Jun 2020

(GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 17 additional news stories.